NCT05626959View on ClinicalTrials.gov

Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

March 1, 2023

Study Completion Date

November 30, 2023

Conditions
Autism Spectrum Disorder
Interventions
DRUG

NTI164

Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.

Trial Locations (1)

3168

Monash Children's Hospital, Clayton

Sponsors
All Listed Sponsors
collaborator

Neurotech International Limited

INDUSTRY

collaborator

Monash Health

OTHER

lead

Fenix Innovation Group

INDUSTRY